Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hypertension is associated with heightened cardiac sympathetic drive whilst statins reduce angiotensin II (ATII) signalling, superoxide anion production and increase nitric oxide bioavailability, events that can potentially reduce peripheral cardiac sympathetic neurotransmission. We therefore investigated whether pravastatin alters peripheral cardiac sympathetic control in the spontaneously hypertensive rat (SHR). SHRs (16-18weeks) had significantly (p<0.05) enhanced atrial3H-norepinephrine (3H-NE) release to field stimulation compared to normotensive WKYs. 2-week pravastatin supplementation significantly reduced3H-NE release to levels observed in the WKY. In-vivo, pravastatin lowered resting heart rate (HR) in the SHR despite not affecting arterial blood pressure or serum cholesterol. In SHR atria/right stellate ganglion preparations, the HR response to stellate stimulation (1, 3, and 5Hz) was also significantly reduced by pravastatin whilst the HR response to exogenous NE (0.025-5μmol) remained similar. The nitric oxide synthase (NOS) inhibitor l-NAME (1mmol/l) increased3H-NE release by similar amounts in atria from supplemented and non-supplemented SHRs, whilst Western blotting showed no difference in protein levels of nNOS, eNOS, guanylyl cyclase, or the NADPH oxidase subunits Gp91 and P40phox. Pravastatin significantly reduced cardiac ATII levels and angiotensin converting enzyme 1 and 2 expressions whilst protein levels of the ATII receptor (ATR1) remained unchanged in the SHR. Immunohistochemistry co-localised ATR1with tyrosine hydroxylase positive neurons in the stellate ganglion. The ATR1antagonist Losartan (5μmol) equalised release of3H-NE to comparable levels in supplemented and non-supplemented SHRs. These results suggest 2-week pravastatin treatment reduces cardiac ATII, and prevents its facilitatory effect on NE release thus normalising cardiac sympathetic hyper-responsiveness in SHRs. © 2010 Elsevier Ltd.

Original publication

DOI

10.1016/j.yjmcc.2010.09.025

Type

Journal article

Journal

Journal of Molecular and Cellular Cardiology

Publication Date

01/01/2011

Volume

50

Pages

99 - 106